GameStop Corp. vs Medtronic PLC — how do they compare? GameStop Corp. trades at $18.53 (market cap $8.44B), while Medtronic PLC trades at $90.61 (market cap $116.07B). The key difference: Medtronic PLC is far larger — about 13.8× GameStop Corp.'s market cap, and Medtronic PLC pays a 3.18% dividend while GameStop Corp. pays none. Which is the better fit depends on your goals.
| GME | MDT | |
|---|---|---|
Market Cap | $8.44B | $116.07B |
Sector | Consumer Cyclical | Health |
52-Week High | $27.69 | $105.35 |
52-Week Low | $18.79 | $73.75 |
Enterprise Value | $4.42B | $134.82B |
Dividend Yield | — | 3.18% |
Signals from Pluang's Aura AI — not financial advice
GME trades at $18.605, down 0.98% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.30 beating expectations of $0.16. Revenue for 2025 was $3.82B, with net income of $131.3M and a profit margin of 3.43%. Recent news highlights a potential shift from a $56B eBay takeover bid to a partnership, as reported by Bloomberg on August 10, 2026.
The outlook is mixed: strong profitability improvements and debt reduction support upside, but analyst consensus is cautious with only 16.67% buy ratings. Key risks include execution of strategic partnerships, competitive pressures in retail, and shareholder dilution from recent debt-for-stock swaps. The stock's valuation appears reasonable with a P/E of 14.04, but sentiment remains divided.
Medtronic (MDT) trades at $90.70, up 1.44% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.55 beating expectations of $1.54. Revenue growth accelerated to $33.54 billion in 2025 with improving profit margins of 13.2%. Recent positive developments include new product approvals and institutional accumulation, though RSI levels suggest potential near-term overbought conditions.
The outlook remains positive with analyst consensus targeting $98.75 (8.9% upside) and no sell ratings. Key opportunities include robotic surgery platform expansion and cardiac ablation growth, while risks involve rising debt levels and competitive pressures. The stock offers dividend stability with a $0.72 upcoming payment, making it attractive for income-focused investors seeking medical technology exposure.
Trailing returns across standard periods
Latest headlines on both assets
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →